The Senate Appropriations Committee's fiscal 2027 bills, released November 10, give FDA two genuinely new assignments — a 90-day cannabinoid-food enforcement report and a 270-day report on botanical pain therapies — while the returning VA medical marijuana study loses last year's one-year reporting expectation. Nothing is law yet: the bills are unnumbered prints with no vote scheduled.
The Senate Appropriations Committee released its fiscal 2027 Agriculture-FDA and Military Construction-VA spending bills on Tuesday, November 10, 2026, and the cannabis language runs in two directions at once. The Food and Drug Administration receives two new assignments involving cannabinoid-food enforcement and botanical therapies for chronic pain. The Department of Veterans Affairs' medical marijuana study returns for another year, but without last year's committee-requested reporting deadline.
One status note applies to everything below: these are unnumbered committee prints, released by the committee majority to stake out a position ahead of the December 11 funding deadline. The committee has not voted on either bill, nothing in them binds anyone yet, and every reporting clock described here starts only if and when a bill is enacted.
FDA faces a new enforcement assignment — and a separate push toward access
The Ag-FDA explanatory statement orders FDA to report to the committee within 90 days of enactment on a coordinated enforcement plan against cannabinoid-containing foods.
The language is pointed: the committee supports FDA's guidance work on "plant or otherwise derived cannabinoids," but notes that "no cannabinoid is approved for any use in food as a food additive," cites the more than 110 warning letters FDA has issued to cannabinoid-product firms since 2018, and asks for an enforcement effort, with federal and state partners, "to protect consumers from unlawfully adulterated foods and food additives in interstate commerce."
Last year's Senate report contained no comparable cannabinoid-food enforcement plan.
The second new item points the other way, toward access. Citing "advanced late-stage clinical trials on botanical, cannabinoid-based therapies for chronic pain" conducted in Europe, the statement urges prioritized FDA review of botanical chronic-pain products and directs the agency to report within 270 days of enactment, "detailing any scientific or regulatory gaps impeding the evaluation of botanical-derived therapies for chronic pain," including whether U.S. review can be harmonized with European evidence.
Last year's chronic-pain language said nothing about cannabinoids.
Together the two items sketch the committee's split posture on cannabinoids: police the food supply harder, and clear a regulatory path for drug-style botanical therapies.
The VA marijuana study survives, but the reporting clock is gone
The Military Construction-VA statement again encourages VA clinical research on medical marijuana and "recommends" that VA study the relationship between state-approved medical marijuana treatment programs, veterans' access to them and "a reduction in opioid use and abuse among veterans."
That language will sound familiar because it is. Last year's report (S. Rept. 119-43) carried the same study and required that "findings should be provided to the Committee on Appropriations of both Houses of Congress within 1 year of enactment."
The fiscal 2027 committee statement omits last year's one-year reporting expectation. The study is recommended again; when, or whether, its findings must reach Congress is no longer specified.
Two other fiscal 2026 VA cannabis items disappeared altogether: language saying that if cannabis moves to Schedule III, VA should consider guidance letting VA doctors discuss, recommend and facilitate access to state medical marijuana programs; and a directive for a report on veterans hurt by VA's policy of barring GI Bill benefits for cannabis-industry courses.
Neither of those two provisions appears in the new statement. Although the word 'cannabis' is absent, the committee does retain a separate medical-marijuana research recommendation.
Psychedelic research moves toward clinical readiness
The VA statement also directs the Secretary to develop a plan to expand VA-led psychedelic research and clinical-implementation readiness, including workforce preparation and system readiness so VA can integrate any future FDA-approved therapies, and to brief both Appropriations Committees on the plan within 180 days of enactment.
It also reminds VA of the previous committee report's direction to collect data for a five-year longitudinal study of veterans participating in these therapies, with findings to be reported at the study's conclusion. It encourages prioritizing research on treatment-resistant PTSD "including but not limited to ibogaine," and separately encourages VA to build a privacy-protected way to count veterans traveling abroad for treatments like ibogaine therapy that aren't available at home.
A companion Ag-FDA item encourages FDA to work with VA, the Defense Department and NIH on psychedelic trials, with an update requested within 180 days of enactment.
No dollar figure is attached to any of the psychedelic items.
Hemp funding rises while the longstanding rider stays in place
The one cannabis-adjacent dollar figure in either bill is the USDA Hemp Production Program: the committee recommends $12,996,000, up from $10,000,000 enacted for fiscal 2026, an increase the committee's summary says the administration requested.
Three hemp research items for the Agricultural Research Service, cultivar development, a germplasm repository, and production-systems research, return at no less than fiscal 2026 funding levels. All three are carryovers from last year's report.
The bill text itself carries Section 737, the longstanding hemp rider barring federal funds from being used against hemp grown in compliance with the 2014 and 2018 farm laws.
It is an annual provision, not a new protection. Notably, the fiscal 2027 Ag bill contains no language addressing the separate federal hemp redefinition enacted through P.L. 119-37. P.L. 119-103 delayed the effective date of most of those changes until December 11, 2026, although certain provisions took effect November 12.
December 11 is the next deadline, but these bills still have a long way to go
Both bills still need a committee vote, none is scheduled, Senate floor passage, reconciliation with the House's fiscal 2027 versions, and the president's signature before any of the 90-, 180- or 270-day clocks start.
Current stopgap funding runs through December 11, 2026.
So the honest read of the week's cannabis news out of the Appropriations Committee is narrower and more interesting than the headline version: FDA is being handed new cannabinoid homework in both directions — enforcement on foods, and a gaps review for botanical pain therapies — hemp's program line grows by about 30 percent, and the VA's marijuana-and-opioids study survives another year with its reporting deadline quietly removed.
Sources
- Senate Appropriations Committee, FY 2027 Agriculture-FDA bill text and Explanatory Statement (committee prints), released Nov. 10, 2026
- Senate Appropriations Committee, FY 2027 Military Construction-VA bill text and Explanatory Statement (committee prints), released Nov. 10, 2026
- S. Rept. 119-37 (FY 2026 Agriculture-FDA) and S. Rept. 119-43 (FY 2026 Military Construction-VA)
Read next
North Carolina's Incoming Speaker Puts Marijuana Decriminalization "On Top of Everybody's Minds"articles · Nov 11, 2026
Texas Democrats File Three Cannabis Legalization Bills as 90th Legislature Prefiling Opensarticles · Nov 10, 2026
Illinois Agrees to Delay Hemp Act Enforcement for About 250 Businessesarticles · Nov 10, 2026
0 comments